Fisher Asset Management LLC Buys 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Fisher Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 176.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 282,288 shares of the company’s stock after acquiring an additional 180,029 shares during the quarter. Fisher Asset Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $10,961,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Hillsdale Investment Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 12.4% during the third quarter. Hillsdale Investment Management Inc. now owns 225,374 shares of the company’s stock worth $8,751,000 after purchasing an additional 24,800 shares during the period. GSA Capital Partners LLP raised its position in Kiniksa Pharmaceuticals International by 281.9% during the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock worth $3,028,000 after purchasing an additional 57,566 shares during the last quarter. JPMorgan Chase & Co. raised its position in Kiniksa Pharmaceuticals International by 42.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock worth $7,473,000 after purchasing an additional 57,174 shares during the last quarter. Aberdeen Group plc acquired a new position in Kiniksa Pharmaceuticals International during the 3rd quarter worth about $6,163,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $351,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA opened at $47.27 on Thursday. Kiniksa Pharmaceuticals International, plc has a one year low of $18.25 and a one year high of $49.12. The company has a market cap of $3.58 billion, a PE ratio of 63.88 and a beta of 0.06. The firm has a 50-day moving average of $43.16 and a 200-day moving average of $40.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. During the same quarter last year, the company posted ($0.12) EPS. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. On average, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Eben Tessari sold 12,048 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the transaction, the chief operating officer owned 16,666 shares of the company’s stock, valued at $692,638.96. This represents a 41.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barry D. Quart sold 2,690 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $564,570. This trade represents a 17.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 123,623 shares of company stock valued at $5,236,389 in the last ninety days. 53.48% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Wells Fargo & Company upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 target price for the company. Finally, Wedbush upped their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.